ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SDEV / news
TENX (27) TELO (28) MAIA (32) QUCY (28) ⌘ Pro Terminal →

Why SDEV Stock dropped -8.91% Today — RQD Quant Desk Flash

$0.92 -8.91% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.90

Stablecoin Development Corporation (SDEV) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $67.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SDEV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SDEV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Stablecoin Development Corporation (NYSE: SDEV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.92 (-8.91% 1D, market cap $67.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SDEV ranks #692 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SDEV compare to TENX and TELO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDEV carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, SDEV leads on earnings multiple (N/A) while SDEV leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SDEV?
▼

Per SDEV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001389545), Stablecoin Development Corporation generated $23.6M in revenue (+141.6% YoY), -$630.8M in net income, and -$8.4M in free cash flow against $9.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.90 (-1.79%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (5)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
$105 Bull$1 Base$1 Bear
📬 FREE SDEV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SDEV)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY SDEV SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$0.99+11.1% Next Q
Q2 (-2Q)
38
Grade E$1.10-1.8% Next Q
Q3 (-1Q)
36
Grade E$1.08-14.8% Next Q
Current
33
Grade E$0.92-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SDEV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SDEV currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.44) and Max Pain ($0.97) forces dealer call-delta covering toward $104.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SDEV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SDEV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why SDEV Stock dropped -8.91% Today — RQD Quant Desk Flash

Stablecoin Development Corporation (SDEV) dropped -8.91% to $0.92, trading at 2% of its 52-week range ($0.78 – $99.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($0.78 – $99.75) with RSI-14 at 43.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.92 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SDEV Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SDEV)

  • ✓Walkthrough of SDEV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SDEV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.66%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.01H $1.01L $0.92C $0.92VOL 3.25M
RES: $11.55SUP: $0.75SMA50: $1.44SMA200: $2.15
$10.45$7.83$5.21$2.59$-0.03RES $11.55SUP $0.75$0.922026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SDEV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SDEV Butterfly Map → + Track SDEV →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +141.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SDEV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SDEV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SDEV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SDEV)

Health Care Rank #692 of 1015 ⚔️ TENX vs SDEV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SDEV vs. TENX, TELO, MAIA, QUCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Stablecoin Development Corporation (SDEV) ranks #692 by composite RQD confidence (33/100, grade E) and #703 by equity capitalization ($67.3M). Within this direct 5-issuer industry benchmark cohort, SDEV leads on earnings valuation at N/A trailing P/E, while SDEV leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SDEV currently leads its immediate peer cohort in composite quantitative strength at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SDEV ACTIVE
Stablecoin Development Corporation
E 33/100 — — -35.0% -8.91% $67.3M Benchmark Subject
TENX
Tenax Therapeutics Inc.
E 27/100 — — -35.0% +0.56% $67.4M /tenx-vs-sdev →
TELO
Telomir Pharmaceuticals Inc.
E 28/100 — — -35.0% -2.15% $67.4M /telo-vs-sdev →
MAIA
MAIA Biotechnology Inc.
E 32/100 — — -35.0% 0.00% $67.9M /maia-vs-sdev →
QUCY
Quantum Cyber N.V.
E 28/100 — 72.6% -35.0% -9.61% $66.2M /qucy-vs-sdev →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001389545 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stablecoin Development Corporation (SDEV) reported GAAP revenue of $23.6M (+141.6% vs. FY2024 revenue of $9.8M , and +105.7% cumulative change since FY2023) , GAAP net income of -$630.8M, operating cash flow of -$8.4M, and free cash flow of -$8.4M (-12.4% YoY). On the balance sheet, SDEV closed FY2025 with $9.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $23.6M -$630.8M -$8.4M -$8.4M $9.0M —
FY2024 (FY) 2024-12-31 $9.8M -$7.2M -$7.5M -$7.5M $3.4M —
FY2023 (FY) 2023-12-31 $11.5M -$9.6M -$4.1M -$4.1M — —

3. SDEV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SDEV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Stablecoin Development Corporation (NYSE: SDEV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.92 (-8.91% 1D, market cap $67.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SDEV ranks #692 in composite RQD confidence.

How does SDEV compare to TENX and TELO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDEV carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, SDEV leads on earnings multiple (N/A) while SDEV leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SDEV?

Per SDEV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001389545), Stablecoin Development Corporation generated $23.6M in revenue (+141.6% YoY), -$630.8M in net income, and -$8.4M in free cash flow against $9.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SDEV trading relative to its 50-day, 200-day, and 52-week technical levels?

SDEV last traded at $0.92 (-8.91% on volume of 3,251,513 shares), positioning the stock -36.11% below its 50-day simple moving average ($1.44) and -57.21% below its 200-day simple moving average ($2.15). Across its 52-week range of $0.78 to $99.75, SDEV sits at the 0.1% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.04).

Direct Sub-Reports: SDEV RQD Cockpit SDEV 12M Forecast SDEV Earnings & Move SDEV Dividends & DRIP SDEV Insiders & 13F SDEV Whale Options SDEV Profit Sankey SDEV News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

SDEV — Stablecoin Development Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Stablecoin Development Corporation (SDEV) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.92 (-8.91% 1D, market capitalization $67.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -10.68%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Stablecoin Development Corporation (SDEV) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $67.3M, gross margin of —, operating margin of —, and return on invested capital (ROIC) of -35.0%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Stablecoin Development Corporation (SDEV) reported $23.6M in annual revenue (up from $9.8M in FY2024, +141.6% YoY) and -$630.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.5M revenue, -$9.6M net income) through FY2025, SDEV scaled operating cash flow to -$8.4M and free cash flow to -$8.4M, backed by $9.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.68% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.78 – $99.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The 2nd-order bottleneck to watch is the reliance on token-linked holdings for any perceived value, since the graph provides no independent supply-chain validation.

  • Key Question #1: Can SDEV sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $23.6M and free cash flow of -$8.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SDEV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SDEV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Stablecoin Development Corporation (SDEV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SDEV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SDEV Bull vs. Bear Conversation Board — What's Your Call at $0.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SDEV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SDEV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.17 (+15.8%)
📌 Pinned Debate

The stock has shown large speculative price swings tied to SKY token holdings, which could attract momentum-driven buying.

Picked up a starter position in SDEV in my $100K Virtual Cash book at $1.01. The stock has shown large speculative price swings tied to SKY token holdings, which could attract momentum-driven buying.. Trading inside a $0.78–$99.75 52-week range with -10.68% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — SDEV's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.83 (-17.8%)
Spot @ $1.01

The company is loss-making with negative ROIC and FCF yield, a Piotroski F-Score of 2 out of 9, and no analyst coverage.

Fading this rally in SDEV at $1.01. The company is loss-making with negative ROIC and FCF yield, a Piotroski F-Score of 2 out of 9, and no analyst coverage.. With a beta of 1.0 and the stock sitting at $1.01 (52-wk range $0.78–$99.75), the easy multiple expansion is already priced in.

LIVE TAPE